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ABSTRACT 
 
Alajman, Amal Fahad. M.S., Microbiology and Immunology Graduate Program, 
Wright State University, 2016. Comparing Antibody-Coated Immune Beads With 
Flow Cytometry to Measure β-2-Microglubulin+ Murine Spleen Cells.   
 
In diseases like AIDS, Multiple Myeloma, Multiple Sclerosis (MS), Type 1 Diabetes, and 
Systemic Lupus Erythromatosus the detection of major histocompatibility complex type 1 
molecules (MHC 1) can be a helpful component of disease diagnosis and prognosis.  
Most somatic mammalian cells display to varying degrees major histocompatibility 
complex (MHC) class 1 antigen on the cell surface. MHC1 molecules consist of a 
polymorphic alpha α chain and a monomorphic beta chain, beta 2 microglubulin (β2m).  
The β2M composition is fairly constant within a species whereas the alpha chain is not. 
The polymorphic alpha chain is encoded by an MHC complex gene that is specific for 
each member of the species. The consistency of the β2M protein within a species makes 
it a superior target to the variable α chains when attempting to quantify MHC1 molecules. 
Currently, there are no reagents available to identify the MHC1 antigen within an outbred 
population such as human or laboratory animals other than defined in bred mouse strains. 
In this study, the presence of MHC1 molecules on spleen cells from an outbred mouse 
strain (ICR strain) was evaluated by looking for monomorphic β2m molecules. The two 
methods, which were used to obtain the numbers of β2m+ mouse spleen cells, were flow 
cytometry and the antibody-latex bead method. Similar numbers of β2m- positive cells 
were obtained using these two methods (7-9%). These results demonstrate that the 
antibody-coated beads are a suitable, less expensive and time saving alternative to 
determine the numbers of β2m+ positive cells when compared to flow cytometry. 
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HYPOTHESIS 
 
The hypothesis of our study is that the using antibody coated latex beads will give 
comparable results to those of flow cytometry in detecting cells bearing the light chain of 
MHC I. 
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Introduction 
This study is a continuation of the work of Sana Alhawsawi who used 
immunohistochemistry to detect the expression of the polymorphic alpha chain and β -2-
microglobulin (β2m) of the major histocompatibility complex I (MHCI) in different 
mouse tissues (spleen, stomach, small and large intestine). She found no difference in 
expression using antibodies specific for the alpha-chain verses the β -2-microglobulin.  
The goal of the present study was to quantitate the expression of β -2-microglobulin on 
mouse spleen cells using flow cytometry and direct counting of cells attached to 
antibody-coated latex beads.  
Flow cytometry detects single cells through laser detector beams. The procedure 
of the flow cytometry starts by using fluorescent-labeled antibodies specific to cell-
surface markers that are selected to show the cell population of interest (Jahan-Tigh, 
Richard R., et al. 2012). This entire process lasts approximately 10 hours. The cost of 
flow cytometry ranges from $30,000 to $150,000 (Matthews, 2006). Developed and 
developing countries could both benefit from a faster and more affordable method to 
detect cell populations of interest.  
  The beads method involves microscopically counting cells attached to latex 
beads. In this study, latex spheres were coated with a β -2-microglubulin rabbit 
polyclonal antibody and used to enumerate the numbers of single positive β -2-
microglubulin+ cells in a suspension of mouse spleen cells.  
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Super Active Latex Beads 
 
There are five types of Super active latex beads: carboxylate modified beads 
(CML), chloromethyl beads, aldehyde/amidine beads, aldehyde/sulfate beads, and 
aliphatic amine. The functional groups of super active latex beads have a very high 
density for covalent coupling of proteins to the particles. The super active layer consists 
of a three- dimensional layer that raises the colloid stability of the particles and makes it 
easier for the protein to bind to the particles. This type of bead maintains the protein 
structure more than the distortion of proteins caused by absorption onto a rigid surface 
("Super Active Latex Beads," n.d.). 
Carboxylate-modified beads are composed of latex polymer particles that have 
highly charged and relatively hydrophilic surfaces with a pka of 5-9. These features 
create a perfect site for covalent bond formation with the antiβ-2 macroglobulin rabbit 
polyclonal antibody coating and present less distortion of the antibody structure ("Super 
Active Latex Beads," n.d.). 
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Literature Review 
 
There are two major defensive systems against different kinds of pathogens: 
Innate and adaptive immune systems (Abele and Tampe, 2004).  Genes of the host germ 
line encrypt the innate immune system while the genes of the host somatic line encrypt 
the adaptive immune system (Abele and Tampe, 2004).  
 Two types of cells are responsible for antigen recognition in the adaptive immune 
system: B and T cells. The B cells have evolved in humoral immune response. T cells 
associate with major histocompatibility complex (MHC) molecules in recognition of 
antigenic peptides (Abele and Tampe, 2004).   
The major histocompatibility complex (MHC) 
The major histocompatibility complex (MHC) is essential part of the immune 
system in all vertebrates by presenting peptides to T cells. The MHC gene is divided to 
two groups, MHC class I, and MHC class II. MHC molecules can mediate the interaction 
of white blood cells (WBCs), which are also known as leukocytes with each other or with 
other cells in the body. MHC genes specify the human leukocyte antigens (HLA) 
(Hughes and Yeager, 1998). 
The MHC class I  
MHC class I molecules are located on every nucleated somatic cells (Reche and 
Reinherz, 2003). MHC class 1 molecules present the antigens from cytosolic 
(intracellular) proteins to T cells that express the CD8 cell-surface glycoprotein 
(Bjorkman and Parham, 1990). Consequently, the process of MHC class I presentation is 
called the cytosolic or endogenous pathway. Virus specific cytotoxic T lymphocytes 
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(CTL) bind to somatic cells that present MHC class I molecules on cell surface for 
peptides that derived from viral antigens and eradicate infected cells (Hewitt, 2003). 
MHC class I antigens contain two polypeptide chains, variable heavy (α chain) 
and light chains (β2microglobulin). The α chain has three domains α1, α 2, and α 3. The 
variable heavy chain (α chain) is polymorphic and encoded by human genes called HLA-
A, HLA-B, and HLA-C (Figure 1) (Bernal et al., 2012).  
The two chains (α and β2-microglobulin) are bound together by a non-covalent 
bond via the interaction between β2m and the α3 domain. The α3 domain binds to the 
CD8 co-receptor on T cells. On the other hand, the α1-α2 heterodimer bind to T cell 
receptor (TCR) on cytotoxic T cell (Bernal et al., 2012). Peptides that attached to MHC 
class I glycoproteins are 8-10 amino acids long (Gil-Torregrosa et al., 1998). 
 The β2m chain is monomorphic and is encoded by the β2m gene. The 
composition of β2m is constant in every cell of a given species. The β2m protein is small 
enough to be filtered by the glomerular membrane and be completely reabsorbed by the 
proximal tubule back into the blood. Hence, serum levels have a significant impact on 
glomerular function in disease conditions. If glomerular function is damaged, serum 
levels increase in reverse ratio to glomerular filtration rate (Karlsson et al., 1979). In 
some diseases including Multiple Myeloma, Multiple Sclerosis (MS), AIDS, Type 1 
Diabetes, and Systemic Lupus Erythromatosus the expression of the β2m chain in major 
histocompatibility complex type 1 molecules (MHC 1) can be a useful factor in disease 
diagnosis and prognosis (Fernando et al., 2008). The polyclonal antibody against β2m is 
easy to use, inexpensive, and is readily accessible in non-specialized laboratories 
(Delgado et al., 2009).  
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The MHC class II 
MHC class II molecules are usually found on antigen presenting cells such as 
dendritic cells, macrophages, mononuclear phagocytes, and some endothelial cells, and B 
cells (Reche and Reinherz, 2003). MHC II molecules present antigens that derive from 
extracellular proteins to T cells expressing the CD4 cell-surface glycoprotein (Bjorkman 
and Parham, 1990). The pathway of MHC class II of antigen presentation is called the 
endocytic or exogenous pathway.  
 MHC class II molecules are similar to MHC class I molecules, in that they are 
also heterodimers, but MHC class II molecules consist of two polymorphic peptides 
chains (α and β chains).  Both of these chains consist of two domains, α1, α2, β1, and β2 
that are encoded within the HLA gene (Figure 1). Since the antigen -binding groove of 
MHC class II glycoproteins is open at both ends, it binds to peptides between 15 and 24 
amino acids in length. In contrast, the antigen binding groove on class I molecules is 
closed at each end and binds smaller peptides (8-12 amino acids) (Ting and Trowsdale, 
2002). 
The expression of MHC class II is stimulated by INF-γ at the transcriptional level 
(Ting and Trowsdale, 2002). The expression of MHC-II glycoprotein is activated via the 
initiation of the protein tyrosine kinases JAKI and JAK2 signaling cascade, leading to 
tyrosine phosphorylation, and STAT1 dimerization. Subsequently, STAT1 dimers are 
transported to the nucleus where they attached to IFN-γ-activated sequence (GAS) 
elements in the promoters of IFN-γ genes (Giroux et al., 2003). 
 6 
INF- γ is a cytokine that plays a critical role in the innate and adaptive immunity 
against viral, bacterial and protozoa infectious agents. In the immune system, IFN-γ 
directly prevents viral replication. IFN-γ also regulates antigen presentation, proliferation, 
and differentiation of lymphocytes. Furthermore, high levels of IFN-γ serve as an 
indicator of T helper 1 (Th1) activity in stimulating the phagocytic actions of 
macrophages (Billiau et al., 1998). Natural killer cells (NK) and natural killer T (NKT) 
cells produce INF- γ as part of the innate immune response, while the CD4 Th1 and CD8 
cytotoxic T lymphocyte (CTL) as part of adaptive immunity (Ting and Trowsdale, 2002). 
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Figure 1. Schematic diagram that shows the differences in the structure of two classes 
of major histocompatibility complexes (MHC). MHC class1 contains three α-domains 
and oneβ-2microglubulin molecule. The peptide-binding groove is found between α1 and 
α2 domains. MHC class II has two α-domains and two β-domains. The peptide-binding 
groove is found between α1 and β1 domains (Modified from Zhong et al., 2011). 
 
 
 
α2	
	
	
	
	
	
α3	
	
α1	
β2	
Cell	membrane		
MHC	I	
α1	
α2	
β1	
β2	
	
Cell	membrane		
MHC	II	
 8 
MHC class I pathway for antigen presentation  
The peptides binding to the MHC class I are generated by the 20 S proteasome 
(Lehner et al., 1998) and the assembly of MHC class I molecules occurs in the 
endoplasmic reticulum (ER) lumen by the formation of β-2-microglubulin dimers 
(Figure. 2) (Ortmann et al., 1997) Two subunits LMP2 and LMP7 are essential for 
degradation of cytosolic proteins to small peptides (Lee et al., 1999). The transporter 
associated with antigen processing (TAP) facilitates the translocation of the peptides 
from the cytosol into the ER lumen (Neumann and Tampe, 1999).  
Two stages are involved in the formation of MHC1 glycoprotein in endoplasmic 
reticulum (ER) in: the early phase and the later phase. The folding of the alpha chain α 
with the β2m chain occurs in the early stage. The late phase involves the formation of the 
‘peptide-loading complex’ (PLC). In the early stage, monoglycosylated 
(Man9GlcNAc2Glc1), which is sugar that chemically associated at position 86 of α chain 
with conserved asparagine. This facilitates the binding between the trans-membrane 
domain of α chains in MHC class 1 and chaperone calnexin (Antoniou and Powis, 2008). 
The structural domain of calnexin (glycan protein) promote the binding of MHC class 1-α 
chains with the extended proline-rich domain and helps the formation of a ‘folding cage’ 
for the early phases of assembly. However, the proline-rich domain recruits oxido-
reductase ERp57, which is one member of the protein disulphide isomerase family that 
can decrease, oxidize or isomerize disulphide bonds. In the late stage, MHC class I α 
chains binds to the immunoglobulin-binding protein (BiP).  BiP binds temporarily, or for 
a long period either to newly synthesized or misfolded proteins in the MHC I α chains 
(Antoniou and Powis, 2008). After that, the calnexin is transported by another soluble ER 
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lectin, calreticulin, which involves prolonged proline- rich domain that recruits ERp57 
(Antoniou and Powis, 2008). The calreticulin binds to TAP to form the peptide loading 
complex (PLC) with the help of Tapasin (TPN), which is an accessory molecule of MHC 
I. PLC is very critical to assisting appropriate MHC I loading before the entire complex is 
transfered to the cell surface. The peptide-loading complex (PLC) coordinates peptide 
transport and recognition in addition to the efficient loading of high-affinity peptides onto 
MHC I glycoproteins (Blees et al., 2015). When MHC class I molecules dissociate from 
TAP, they are transferred to the cell surface by cargo vesicles for transfer to the Golgi. 
Then, MHC I molecules display their antigen cargo to Cytotoxic T lymphocytes CTLs 
(Figure 2) (Hewitt, 2003). 
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Figure 2.The MHC class I antigen presentation pathway.  
First, proteasome generate the proteins in the cytosol. Then, peptides translocate into the 
ER lumen by TAP.  ER chaperones calnexin, calreticulum and ERP57 facilitates the 
MHC class I molecules folding and assembly in the ER. When Peptides bind to MHC 
class I molecules, it dissociates from TAP and then is transported to the plasma 
membrane (Modified from Hewitt, 2003).  
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MHC class I on Human and Mouse 
In humans, the α chains of MHCI are different than that found in mice. The α 
gene of MHCI is known as human leukocyte antigen (HLA) and displays three-class 
loci (A, B and C) known as HLA-A, HLA-B, and HLA-C (Pick et al., 2012). While in 
mice, the MHC I α chain is coded by the H-2 gene. The MHC I H-2 gene presents three 
loci (K, D, and L). In each locus, both alleles are expressed, so these genes are extremely 
polymorphic. For example, HLA-B gene has about 500 known alternative genes, over 
200 variants of HLA-A genes, and about 100 variants of HLA-C genes (York and Rock, 
1996). In humans, the major histocompatibility complex class I is found on the 
chromosome 6 while in mice it is located on the chromosome 17  (Relle and Schwarting, 
2012). In humans, β2m is found on chromosome 15 while in mice is located on 
chromosome 2. One allele is found in humans, whereas seven alleles are found in mice 
(York and Rock, 1996).  
Biological roles of MHC I  
 Beside the well-known role of human MHC I glycoprotein in the immune 
response, some studies have indicated that human MHC I plays a role in some 
autoimmune and inflammatory diseases. MHC I seems to be important in the 
pathogenesis of multiple sclerosis (MS), Crohn’s disease (CD), type 1 diabetes (T1D), 
ulcerative colitis (UC), systemic lupus erythematosus (SLE), and rheumatoid arthritis 
(RA) (Fernando et al., 2008). MS affects the central nervous system and is a chronic 
inflammatory syndrome and T1D is a chronic autoimmune disease described by T cell-
mediated impairment of pancreatic cells, which results in insulin insufficiency. SLE, also 
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known as lupus, is an autoimmune disease that can affect multiple organ systems. Lupus 
is a genetic disease linked to the genes of the major histocompatibility complex 
(MHC)(Relle and Schwarting, 2012). CD and UC are inflammatory bowel diseases of the 
gastrointestinal tract. Rheumatoid arthritis (RA) is a chronic inflammatory polyarthritis 
which often will have systemic symptoms (Fernando et al., 2008). In inflammatory bowel 
disease (IBD) patients, the activity of β2m may enhance the activation of macrophages 
and T-lymphocytes (Yılmaz et al., 2014).  In autoimmune diseases, the immune response 
of the body is abnormal in that it attacks antigens and tissues that are normally present in 
the body (Relle and Schwarting, 2012). The role of human MHC I in autoimmune 
diseases is not well understood, but the main cause for autoimmune diseases could be due 
to the disequilibrium alleles at multiple loci in the human MHC I (Fernando et al., 2008).  
 MHC I has an important role in transplantation complications, including graft 
rejection in human liver. In healthy liver tissue of humans, the expression of both chains 
of MHC 1 is very low (Steinhoff, 1990). In a liver transplant, the recipient’s immune 
system targets the donor cells causing graft rejection. During rejection and after liver 
transplantation, the level of human MHC I protein is increased notably in the plasma 
membrane of the hepatocytes, epithelia, endothelia, and Kupffer cells (Steinhoff et al., 
1990). The MHC I molecule has to be compatible in both donor and recipient cells in 
order for grafts to be accepted (Carcia et al., 2012). 
In brain development, the function of MHC class I in human is similar to its 
function in mice. The genes of both MHC class I and β2m are expressed in humans and 
mice during cerebellar cortex development (Lv et al., 2014). The expression of H-
2Kb/Db and HLA-B/C molecules increase during the growth of the brain in mice and 
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humans, respectively, but they both decrease after birth (Lv et al., 2014). These findings 
emphasize the role of MHC class I in plasticity and synaptic remodeling during cerebellar 
development.  
Recently it has been discovered that MHC I is expressed on neurons (Cebrián et 
al., 2016). There is evidence that expression of MHC I is necessary for the development 
of the brain structure involved in memory (Cebrián et al., 2016). Furthermore, an 
overexpression of neuronal MHC I also appear to play a role in neurodegenerative 
disorders like Parkinson’s disease (PD) (More et al., 2013). 
β2-microglobulin 
 All nucleated cells synthesize β2microglobulin polypeptide and it is found in most 
cells. It forms the light chain of MHC class I (Chelazzi and Senaldi, 1986). It has a low 
molecular weight 11,800 kDa and has structure that is similar to the constant region of 
immunoglobulin molecules (IgG). This protein can be isolated from human urine 
(Manicourt et al., 1978). β2m is not significantly polymorphic and is similar in all 
mammals (York and Rock, 1996). β2m is a non-glycosylated protein and consists of 100 
amino acids. The level of normal serum β2m is usually less than 3mg/L, but in elderly 
people it gradually increases. Kidneys play an important role in β2m catabolism as 
evidence by the high serum levels of β2m in the renal failure patients (Chelazzi and 
Senaldi, 1986). High serum levels of β2m are present in neoplastic and non- neoplastic 
diseases, and acquired immunodeficiency syndrome (AIDS). Also, β2m is useful marker 
in the evaluation of the multiple myeloma (Chelazzi and Senaldi, 1986). Many studies 
show that the level of serum β2m may be elevated abnormally in patients with different 
types of malignant tumors, as compared to controls (Forman, 1982).  
 14 
 
Serum β2 microglobulin and diagnosis of human disease 
Serum β2 microglubulin has been determined as an important prognostic marker 
in several diseases such as hematologic malignancies and non-hematologic disorders 
(Yang et al., 2006) .The levels of β2 microglubulin were elevated in lymphoma 
proliferative disorders including multiple myeloma, and chronic lymphocytic leukemia 
(Henne et al., 1996). In 1982, Bataille et al found that the levels of serum β2m were 
significantly elevated in patients with multiple myeloma at time of diagnosis comparable 
to normal individuals (bataille et al., 1982). Also, the levels of serum β2m in multiple 
myeloma seem to correlate well with survival time. Patients with the highest level of 
serum β2m have the shortest survival (Bataille, and Grenier, 1987). In addition, there is a 
correlation between the levels of serum β2m and the stage of the multiple myeloma 
disease. In the late stage of the disease, patients have higher levels of β2m than in the 
early stage of the disease (Chelazzi and Senaldi, 1986). The elevation of serum β2m in 
multiple myeloma indicates it functions to increase inflammation (Prizment et al., 2014). 
 
In the immune system, the propagation of B cells and the production of antibodies 
are tightly regulated. In multiple myeloma, usually the chromosomal translocation occurs 
between the immunoglobulin heavy chain gene (on chromosome 14, locus q32) and an 
oncogene (often 11q13, 4p16.3, 6p21, 16q23 and 20q11). This results in dysregulation of 
the oncogene, which is the initiating consequence in the pathogenesis of myeloma. (Kyle 
and Rajkumar, 2004). In addition, the serum of patients with renal failure will have high 
levels of β2 microglubulin. In patients with healthy kidneys, the normal serum levels of 
β2 microglubulin are 1.5 to 3-mg/L while in renal failure, the levels increase by 60-fold 
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and more (Winchester et al., 2003).  
The levels of serum β2 microglubulin are elevated in human Immunodeficiency 
virus (HIV) infection, acquired immune deficiency syndrome (AIDS), and autoimmune 
disorders such as rheumatoid arthritis. However, the high level of β2 microglubulin can 
activate or inhibit the immune system. For example, in HIV patients, the high level of 
serum β2 microglubulin is associated with progression to AIDS while the levels of serum 
β2 microglubulin correlates with poor prognosis in the hematologic malignancies (Xie et 
al., 2003).  
Disease conditions associated with elevated levels of serum β2 microglubulin 
include multiple sclerosis, meningeal dissemination, and sarcoidosis (Adachi, 1991). 
Increase the serum levels of β2m are due to that the β2 microglubulin is shed from the 
surface of nucleated cells into serum during these diseases. These syndromes are 
involved with activation of the immune system and/or increased cell turnover (Gooptu et 
al., 2014).   
Staging of multiple myeloma 
 Multiple myeloma is a malignancy of B- lymphocytes. These malignant 
lymphocytes express more β2m (Kumar et al., 2008). International myeloma working 
group (IMWG) has described a staging system of multiple myeloma known as 
international staging system (ISS) based on two factors: β2m, and serum albumin (Raja, 
2012). The level of serum β2m is normally less than 2mg/L (Xie et al., 2003), but in 
multiple myeloma it increases up to 5.5 mg/L (Raja, 2012). International staging system 
(ISS) has been described three stages of Multiple Myeloma (Raja, 2012). In stage I, the 
level of Serum β2 microglobulin is <3.5-mg/L and albumin ≥3.5 g/DL and the survival 
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duration is an average of 62 months. In stage II, the survival duration is 44 months and 
the β2 microglobulin is ≥5.5 mg/L and the patients survive up to 29 months (Raja, 2012). 
The high levels of serum β2m in multiple myeloma are associated with increased cell 
proliferation (Karlsson et al., 1979).  
  
β2-microglobulin as a negative regulator of the immune system 
 Dendritic cells (DCs) are key cellular immune elements in peripheral tissues. 
When DCs encounter pathogens, they are activated and travel to the secondary lymphoid 
organs, where they stimulate a specific T-cell response (Xie et al., 2003). DCs are the 
most effective antigen presenting cells (APCs) and can stimulate different cells including, 
naïve CD4+ and CD8+ T cells and B cells. DCs can initiate both the primary and the 
secondary immune response. DCs are the key targets for some conditions that involve an 
alteration T cells activity, such as transplantation, autoimmune disease, some cancers, 
and immunodeficiency. However, high levels of β2-microglobulin have a negative impact 
on the immune system. Cells that are treated with β2-microglobulin had decreased 
antigen presentation capability and enhance tumor growth and survival by producing 
cytokines, such as IL-6, IL8, and IL-10. These cytokines induced the secretion of weaker 
IL-2 and INF-ϒ that activate T-cell responses, and compromised DC ability to mount a 
type I T-cell response. β2-microglobulin treated cells inhibit the Raf/MEK/ERK signal 
transduction cascade and activate STAT3, a protein that has a crucial role in cell growth, 
proliferation, and survival (Xie et al., 2003). 
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Materials and Methods 
 Animal model.  
 Spleens were harvested from three month old ICR female and male mice by Dr. 
Emily Dudly and placed in Dulbecco’s Modified Eagle’s Medium (DMEM) (HyClone, 
Fisher Scientific, Pittsburgh,Pa). The spleen was macerated between the frosted ends of 
two suspended microscope slides. The spleen cells were in 5 ml 1X PBS and centrifuged 
for 5 min at 1500rpm.  To sediment the cells, the cells were re-suspended in 5ml 1x PBS 
and quantified using both the beads method and flow cytometry.  
The use of antibody-coated beads to detect β2microglubulin on cells  
By using these antibody-coated beads, the cell suspension or the β2m marker can 
be counted under light microscopy. The beads method requires three reagents: labeling, 
blocking, and staining reagents.  The labeling reagent, the antiβ-2 macroglobulin rabbit 
polyclonal antibody (Santa Cruz Biotechnology, INC) was coated on 1.4 μm carboxylate 
modified super active latex beads (Life Technologies, Grand Island, NY). 20% normal 
rabbit serum (Sigma-Aldrich, St.Louis, MO) is used as blocking agent (with 3% BSA and 
5% tween).  The blocking reagent limits the non -specific binding.  The staining reagent 
can lyse red blood cells and contains 0.025% crystal violet stain and 2% acetic acid in 
distilled water.   
  The passive adsorption method was used on the labeling reagent to coat the beads. 
Attachment of antibodies to carboxylate modified super active latex beads occurred by 
physical adsorption. The MES buffer (Fisher Scientific, Pittsburg, PA) (0,025M,PH6, 
wash buffer (phosphate buffered saline, 0.1M, PH 7.2), and storage buffer (phosphate 
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buffered saline, 0.1M, PH 7,2, 0.1 glycine, 0,1% NaN3) were used. The high value of the 
pH of MES buffer is identical to the isoelectric point of the β-2 microgubulin. Therefore, 
it will increase the protein density on the particle surface (“Passive Adsorption Protocol,” 
n.d.).  
MES buffer Preparation (2- N-Morpholino-EthanesulfonicAcid)   
48.8 mg of MES was weighted and added to 5 ml of double distilled water. Then, 
1 N NaOH was added in order to increase the PH value (Appendix 1).  
Storage Buffer preparation 
100 mg glycine was mixed with 100 mg sodium azide, then the volume was 
brought to 10 ml PBS (Appendix 1).  
The quantities of Antibody and super latex beads 
The following equation determines the amount of antibody required for coating 
beads:  
𝑤𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑡ℎ𝑒 𝑎𝑛𝑡𝑖𝑏𝑜𝑑𝑦 =  
𝑤𝑒𝑖𝑔ℎ𝑡 𝑡ℎ𝑒 𝑎𝑛𝑡𝑖𝑏𝑜𝑑𝑦 𝑓𝑜𝑟 𝑡ℎ𝑒 𝑡𝑜𝑡𝑎𝑙 𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒 𝑤𝑒𝑖𝑔ℎ𝑡
𝑑𝑖𝑎𝑚𝑒𝑡𝑒𝑟 𝑜𝑓 𝑡ℎ𝑒 𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒 𝑖𝑛 𝜇𝑚
 
(Appendix 1).  
The preparation of the super latex beads labeling with antibody 
 We diluted 2.5 ml latex beads in 10 ml MES buffer. Then, we centrifuged the 
compound for 20 min to 3000rpm. Then, re-suspends the pellet in 10 ml MES buffer. 
And we centrifuged it again at same condition. We re-suspended the pellet in 5 ml MES 
buffer. After that, we added the calculation amount of the antibody and Incubated the 
mixture at room temperature overnight. Then, we centrifuged the latex/ antibody mixture 
and re-suspended the pellet in 10 ml phosphate buffer saline (PBS).  We centrifuged the 
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pellet 3 times for 20 min at 3000 rpm and Re- suspended the final latex of β2m in 5 ml 
storage buffer. The latex was stored at 4 °C ("Passive adsorption protocol"n.d.) 
(Appendix 2).  
 
Counting β2microglubulin by beads method 
For each sample we used two 12 ×75 mm tubes: test tube# 1; label with B+L and 
test tube#2; label with S. We pipetted 100 μl of agent S into the test tube that labeled with 
S. (Figure 3.A). Then, we put 100 μl of spleen cells suspension into the test tube labeled 
with B+L. (Figure 3.B). We added 10 μl of the blocking agent (B) to the spleen cells 
suspension in the tube labeled with B+L. (Figure 3.C). Then, we added 10 μl of the 
Labeling agent (L) to the B+L test tube. (Figure 3.D). We added 10μl from the mixture in 
the B+L test tube to the S tube. (Figure .3.E). By using the hemocytometer (Figure. 3.F).  
Under the light microscope, cells that had three or more latex spheres attached were 
counted as having β2m ("Manual CD4 count kit” n.d.) (Appendix 3). 
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Figure 3.The steps of the bead method. (A-F). Figures demonstrate the steps of the 
bead method. The letter B + L represents blocking reagent + labeling reagent and the S 
letter represents staining reagent. Adapted from ("Manual CD4 count kit" n.d.). 
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Figure 4.The attachment of three or more beads to cells. Images under light 
microscopy demonstrate the attachment of three or more beads to β2m+ cells. 
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Figure 5.No attached beads. 
Images under microscope show no beads attached to the β2m+ cells. 
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Absolute Count 
The cells that have no attached beads (figure 3), one bead attached, or two beads 
attached were excluded from count. One or two attachments of the latex beads to the 
antibody can be by chance and it is non-specific. Three attachments of the latex beads to 
the β2m antibody are more definitive and indicate the binding is not accidental. The 
results of the control experiment indicated that cells never exceeded two beads. The next 
formula demonstrates the absolute counting for β2m+ cells in mice spleen:  
𝛽2𝑚+𝑐𝑒𝑙𝑙𝑠 ∕ 𝔲𝑙 = 
𝛽2𝑚+𝑐𝑒𝑙𝑙𝑠 𝑛𝑢𝑚𝑏𝑒𝑟𝑠 × 𝑐ℎ𝑎𝑚𝑏𝑒𝑟 𝑑𝑒𝑝𝑡ℎ 𝑐𝑜𝑟𝑟𝑒𝑐𝑡𝑖𝑜𝑛 × 𝑠𝑎𝑚𝑝𝑙𝑒 𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑐𝑜𝑟𝑟𝑒𝑐𝑡𝑖𝑜𝑛
𝑠𝑢𝑟𝑓𝑎𝑐𝑒 𝑎𝑟𝑒𝑎(𝑚𝑚2)
 
(Appendix 4).  
Counting β-2microglubulin by Flow Cytometry 
Flow cytometry uses laser beams to analyze the chemicals and physical 
proprieties of any particles in a fluid. It is commonly used for cell counting, sorting, and 
biomarker detection. The process and reagents for surface markers can be very costly.  In 
this study, the flow cytometry were used to count the number of β2m+ cells. The indirect 
antibody was used. For the isotype control, normal rabbit serum (Sigma Aldrich, 
St.Louis, MO) was used. The primary antibody used was the anti-β2m rabbit polyclonal 
antibody (Santa Cruz Biotechnology, Dallas, Texas) and the secondary antibody was goat 
anti- rabbit IgG (FITC)(Santa Cruz Biotechnology, Dallas, Texas). The purpose of the 
isotype control was to measure the level of non-specific background signal caused by 
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primary antibodies. This control was used to distinguish non-specific background 
signals from specific antibody signals.  
 
 The spleen cells suspension was washed three times with 1% BSA (bovine serum 
albumin) and centrifuged at a speed of 1200 rpm for 5 minutes. After that, 3%BSA was 
used for 30 minutes for the purpose of blocking non-specific staining and was incubated 
at room temperature. Then, the cells were washed again three times with 1% BSA and 
centrifuged at a speed of 1200 rpm for 5 minutes.  The fluorochrome conjugated primary 
antibody specific for β2m was added and incubated with the cells for 15 to 45 min 4°C in 
the dark 5 μg antibody / ml with 100 μl of 3% BSA for each sample. Then, cells were 
washed three times with 1% BSA and centrifuged at a speed of 1200 rpm for 5 minutes.  
The secondary conjugated antibody was added and incubated with the cells for 15 to 45 
min 4°C in the dark (Add 0.1 to 10 μg antibody/ml then diluted with 100 ml of 3% BSA). 
Then, the cells were washed and centrifuged again with 1% BSA 3X (1200rpm, 5min). 
Re-suspend the cells on cold PBS, 10% FCS, and 1% sodium azide until analysis within 
24 hours. The results from flow cytometry were analyzed using the FCS Express program 
(Figure 6).  
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Figure 6: Flow Cytometry Analysis of β2-microglubulin polyclonal Antibody (A-E). 
It shows the analysis of flow cytometer of ICR female mouse spleen cells suspension 
using β2-microglubulin polyclonal antibody at 20,000 events. The number of 
β2microglubulin+ cells per sample = 20,000/ volume at which 20,000 was detected 
(Dataanalysis in Table 1-3). 
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Results 
 The number of β2m
+ cells was enumerated by using two different methods; flow 
cytometry and bead method in spleen cells from two three-months-old ICR females and 
three three-month-old ICR males. The overall number of cells in all spleens of ICR 
female and male mice was around 10 million. The results of both methods flow 
cytometry and bead methods are similar and no significant differences between them. It is 
important to note that the bead method results were higher than flow cytometry in terms 
of β2m
+ cell counts. The results were analyzed by using Sigma Plot. The numbers of 
β2m+ cells were between 400-500 cells/ μΙ.  
Table 1 demonstrates the total numbers of β2m
+ spleen cells individual samples 
from five ICR female and male mice by using flow cytometry and bead method. One-
way ANOVA shows that the differences in the mean values between the two methods are 
not great enough and there is not a statistically significant difference (P = 0.058) (Mean 
of the flow cytometry β2m+  = 375 ± 25, and mean of the bead method β2m+ = 466 ± 32, 
mean ± SEM). Table 2 indicates the total number of β2m+ spleen cells per sample. The 
absolute number of spleen cells was approximately 10 million in all samples. 
 In addition, the percentage of the total numbers of single β2m+ cells to the total 
number of spleen cells is presented in Table 3. There were no significant differences 
between the two methods. The percentage of total β2m+ cells to the total spleen cells 
counts was between 7 and 9%.  
We excluded ICR M 2 sample from tables 4, 5, and 6 from our data due to the 
statically insignificant curve of the isotype control.  
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Table 1 
Comparison of β2m+ cell numbers determined by flow cytometry and immunobeads. 
Mouse  Flow cytometry  Bead method  
ICR F 1 313/μΙ 467/ μΙ 
ICR F 2 340/μΙ 394/ μΙ 
ICR M 1 373/μl 408/μl 
ICR M 2 392/μl 576/μl 
ICR M 3 461/μl 489/μl 
Mean ± SEM 375 ± 25/μl 466 ± 32/ μl 
 
In Table 1, β2-microglubulin+ spleen cell counts from female and male ICR mice 
were determined using flow cytometry and the immune bead method. Note that the 
numbers are not significantly different from one another when pairwise comparisons 
were made using one-way ANOVA.  
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Table 2 
Numbers of Single β2-micoglubulin+ Cells Per Sample. 
Mouse Flow cytometry  Bead Method 
ICR F 1 626,000 934,000 
ICR F 2 680,000 788,000 
ICR M 1 746,000 816,000 
ICR M 2 784,000 1,152000 
ICR M 3 922,000 978,000 
Mean ± SEM 751,600±505,07 933,600±650,76 
 
In Table 2, the results are shown for total β2-micoglubulin+ cells in each sample 
as determined by flow cytometry and immune bead. These results were not significantly 
different between the two methods. (One-way ANOVA pairwise comparisons). 
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Table 3 
Percentage of Single β2microglubulin+ Cells / Total Spleen as determined by flow 
cytometry and immunobead counting. 
Mouse  Flow cytometry  Bead Method  
ICR F 1 6 9 
ICR F 2 6 7 
ICR M 1 7 8 
ICR M 2 7 11 
ICR M 3 9 9 
Mean ± SEM 7± 0,5 8± 0,6 
 
In Table 3, no significant difference can be seen in the percentage of β2 
microglubulin+ Cells / Total Spleen cells was found (One-way ANOVA, pairwise 
comparisons). 
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Table 4 
Modified comparison of β2m+ cell numbers determined by flow cytometry and 
immunobeads 
Mouse  
 
Flow cytometry 
 
 
Beads 
ICR F1 
 
313 
 
 
467 
ICR F2 
 
340 
 
 
394 
ICR M 1 
 
373 
 
 
408 
ICR M 3 
 
461 
 
 
489 
Mean± SEM 
 
371±32 
 
 
439±22 
 
 
In Table 4, β2-microglubulin+ spleen cell counts from female and male ICR mice 
were determined using flow cytometry and the immune bead method. Note that the 
numbers are not significantly different from one another when pairwise comparisons 
were made using one-way ANOVA.  
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Table 5 
Modified numbers of β2-micoglubulin+ Cells per Sample. 
Mouse 
 
Flow cytometry 
 
 
Beads 
ICR F1 
 
626,000 
 
 
934,000 
ICR F2 
 
680,000 
 
 
788,000 
ICR M1 
 
746,000 
 
 
816,000 
ICR M3 
 
922,000 
 
 
978,000 
Mean± SEM 
 
743,500± 643,60 
 
 
879,000±457,12 
 
In Table 5, the results are shown for total β2-micoglubulin+ cells in each sample 
as determined by flow cytometry and immune bead. These results were not significantly 
different between the two methods. (One-way ANOVA pairwise comparisons). 
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Table 6 
Modified percentage of β2microglubulin+ Cells / Total Spleen as determined by flow 
cytometry and immunobead counting. 
Mouse 
 
Flow cytometry 
 
 
Beads 
ICR F1 
 
6 
 
 
9 
ICR F2 
 
6 
 
 
7 
ICR M1 
 
7 
 
 
8 
ICR M3 
 
9 
 
 
9 
Mean± SEM 
 
7±0,7 
 
 
8±0,4 
 
In Table 6, no significant difference can be seen in the percentage of β2 
microglubulin+ Cells / Total Spleen was found (One-way ANOVA, pairwise 
comparisons). 
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Discussion 
In this study, we evaluated the expression level of MHC I in murine spleen cells. 
Since the MHC I α chain is encoded by variant HLA-A gene, and the β chain (β2-
microglobulin) is consistent (Bernal et al., 2012), the main purpose of the study was to 
detect the MHC I molecules in mouse spleen cell using an antibody against the β2m 
protein. The aim of the current study was to quantitate the expression of β2m on mouse 
spleen cells using flow cytometry and direct counting of antibody-coated latex beads for 
comparison with the results of Sana Alhawsawi who found no difference in expression of 
spleen cells from C47BL/6 mice staining positive for the alpha-chain of MHCI compared 
to the β2m (S. Alhawsawi, MS Thesis, Wright State University, 2015).  In the present 
study, the numbers of β2m
+ cells in mouse spleen suspensions from outbred ICR Swiss 
mice were also similar using flow cytometry (typical method) and counting antibody-
coated latex beads. In this study, 7-9% of the spleen cells tested positive for β2m-labled 
cells.  This number is low because these cells are obtained from healthy mice. In 
Alhawsawi’s study, she found approximately 10% or less normal mouse spleen cells 
staining for β2m. However, in spleens of mice that were infected with mouse parvovirus 
class I, 80% or greater of the spleen cells stained positive for the β2m chain and for the 
polymorphic alpha chain of C57Bl/6 mice.  
Flow cytometry detects biomarkers, counts and sorts cells by using laser beam 
and fluidics. The flow cytometry technique is more expensive than the bead method. 
Flow cytometry also demands a highly trained person. The reagents of flow cytometry 
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are costly from $30,000 to $150,000 ("Flow cytometry," n.d.). Furthermore, the process 
takes approximately 10 hours.  These factors indicate that we need an alternative method 
to enumerate the β2m+ cells that is cheaper, easier to use, faster, and more accessible. In 
contrast, the reagents of the bead method are not costly when compared to the cost of 
flow cytometry. In the bead method, monoclonal antibody-coated- latex beads associate 
with the surface of the cells that express β2m. When anti-β2m coated -latex beads bind to 
the cell that displays β2m cell surface antigen, this binding forms a cell-latex bead rosette 
that is easily recognized using light microscopy.  
In this study, no statistically significant differences were seen using the bead and 
flow cytometry method for enumerating single β2m+ cells. However, there was a little 
difference in the absolute numbers of β2m+ cells in both methods. The results will be 
more precise when using negative isotype control for beads method. In addition, the 
numbers of β2m+ cells in beads method were higher compared to the flow cytometry due 
to the sequence of the experiments. The results of this study suggest that the bead method 
can be an alternative method to flow cytometry in identifying cell surface antigens.  
These results support those of Allabidi (2014) in which the number of CD4+ and 
CD8+ T lymphocytes in ICR Swiss mouse spleens yielded similar results using both 
methods. In addition, the present study supports the observations of Othman (2015) in 
which he found similar numbers of single mouse spleen cells displaying two surface 
markers  (CD5+ and CD19+) using flow cytometry and antibody-coated latex beads. 
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Future studies 
 
The bead method could be used to diagnose and monitor the progress of treatment 
of metastatic embryonal carcinomas. Several studies have shown that in embryonal 
carcinomas the expression of CD30 is elevated at both protein and mRNA levels. After 
chemotherapy treatment, CD30 + cells are eliminated due to chemotherapy (Berney et al., 
2001). This demonstrates that CD30 could be a factor for stem cell regulation in early 
embryonic development.  
Multiple myeloma is a neoplastic disease of the plasma cells in which the plasma 
cells (PC) proliferate abnormally in the bone marrow (Kumar et al., 2008). One 
characteristic of multiple myeloma is osteolytic bone destruction. Since the levels of β2m 
are highly expressed in patients with multiple myeloma (Raja, 2012), we can detect the 
MHC class I expression by examining the number of β2m+ cells to monitor the disease 
progression. Future studies can be done, by using western blot. Western plot will detect 
the expression of specific intracellular proteins in samples while flow cytometry can be 
used to detect the surface marker in suspended cells.  
Immunohistochemistry (IHC) is a technique that can detect proteins in tissue by 
antibody-antigen binding (Ramos-Vara and Miller, 2014). Since the levels of serum β2m 
are highly expressed in inflammatory bowl diseases such as ulcerative colitis (UC), 
Crohn’s diseases (CD), and rheumatoid arthritis (RA) (Fernando et al., 2008), we can 
detect the expression of antiβ-2 macroglobulin rabbit polyclonal antibody by using 
indirect immunohistochemistry to determine patient’s prognosis. In cases such as 
metastases or carcinoma of unknown origin, immunohistochemistry can be helpful for 
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cell identification. IHC such as that described in this paper can also help distinguish 
between benign and malignant tumors. 
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Appendix 
Appendix 1 
MES buffer Preparation (2- N-Morpholino-EthanesulfonicAcid)   
We weighted 48,8 mg of MES and added it to 5 ml of double distilled water. Then, we 
tittered the PH value by using electrode with 1 N NaOH in order to increase the PH from 4 to 6. 
After that, we transferred the MES buffer to the volumetric flask and diluted it to the final 
volume of 10 ml of PBS (“Passive Adsorption Protocol,” n.d.).  
Storage Buffer preparation 
We weighted 100mg glycine, 100mg sodium azide. Then we mixed them and bring the 
volume to 10 ml with PBS. We used glycine in order to fill any reactive site on the surface that 
does not cover by protein.  Bovine serum albumin (BSA) can be used to decrease non-specific 
binding. On the other hand, the NaN3 is worked as biocide ("Passive adsorption protocol," n.d.). 
The quantities of Antibody and super latex beads 
The following equation determines the amount of antibody required for coating beads:  
� � ℎ   ℎ  � � =  � � ℎ  ℎ  � �  ℎ   �  � � ℎ�   ℎ  �  �  �  
For example, in this study, we coated 100 mg of 1.4 μm latex beads with 2 mg of β2m antibody, 
so the weight of β2m = 2mg⁄1.4 μm = 1.4 mg of β2m antibody is needed to coat 100 mg of the 
super latex beads ("Passive adsorption protocol” n.d.). 
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Appendix 2 
The preparation of the super latex beads labeling with antibody 
1. 2.5 ml latex beads were diluted in 10 ml MES buffer. 
2. Centrifuge the compound for 20 min to 3000rpm. 
3. Remove the supernatant and re- suspend the pellet in 10 ml MES buffer. 
4. Centrifuge again and remove the supernatant. 
5. Re-suspend the pellet in 5 ml MES buffer. (The latex suspension is probably ~ 
20mg/ml). 
6. Add the calculation amount of the antibody. 
7. Incubate the mixture at room temperature overnight. 
8. Centrifuge the latex/ antibody mixture. 
9. Re-suspend the pellet in 10 ml phosphate buffer saline, PH=6. 
10. Centrifuge the pellet 3 times for 20 min at 3000 rpm. 
11. Re- suspends the final latex of β2m in 5 ml storage buffer (the concentration at 2% 
solids). 
12. Store the latex at 4 °C ("Passive adsorption protocol"n.d.). 
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Appendix 3 
Counting β2 microglubulin by beads method 
1. Two 12 ×75 mm tubes were used for each sample.  
a. Test tube# 1; label with B+L. 
b. Test tube#2; label with S. (as in Fig3.A) 
2. Pipette 100 μl of agent S into the test tube that labeled with S. (Fig3.B).   
3. Put 100 μl of spleen cells suspension into the test tube labeled with B+L. (Fig3.C).  
4. Add 10 μl of the blocking agent (B) to the spleen cells suspension in the tube labeled 
with B+L. (Fig3.D) 
5. Immediately, after adding the B agent, gently mix the B+L test tube for 2 min. 
6. Add 10 μl of the Labeling agent (L) to the B+L test tube. (Fig3.E). 
7. After adding the L agent, mix the B+L test tube for 2 min. 
8. Place 10μl from the mixture in the B+L test tube into the S tube. (Fig.3.F). 
9. Mix the test tube gently by hand for 15 sec. 
10. Put the sample from step 9 on both chambers of the 0,1 mm deep hemacytometer.  
11. By using the light microscope, cells that had three or more latex spheres attached to the 
cells were counting as β2m ("Manual CD4 count kit” n.d.). 
12. Under the light microscope, we count the cells that had three or more large latex spheres 
attached as β2m+ cells.  
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Appendix 4 
Absolute Count 
The cells that have no attached beads (figure 3), one bead attached, or two beads attached 
were excluded from count. One or two attachments of the latex beads to the antibody can be by 
chance and it is non-specific. While, three attachments of the latex beads to the β2m antibody are 
more specific and it is not by chance.  
The next formula demonstrates the absolute counting for β2m+ cells in mice spleen:  
� + ∕ � = 
� +   × ℎ  ℎ � ×  � �  � 2  
ℎ  ℎ � = ℎ  ℎ = . =   .    ℎ . 
Correction for sample Dilution= 
A) 100 μl whole sample  
+10 μl reagent L 
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+10 μl reagent B = 100⁄ 120 
B) Secondary dilution= 
10 μ of 100⁄ 120 primary dilution in 100 μl reagent C = 
� × �  = .  
Therefore the correction for sample dilution = 
÷ .  = .  
Surface area = 18 2 for two sides of 0.1 mm deep chamber ("Manual CD4 count kit," n.d.) 
For example, if the count β2+ cells in both sides of 0.1 mm chamber were 50 the β2m+ cells count 
can be calculated by applying the next formula: 
× ℎ  ℎ � ×  � �  � . 2  
× . =  � + ∕ � . 
 
  
 
